Company News: Celgene and Abraxis BioScience

Share this article:
New Jersey-based biotech Celgene announced an agreement to purchase Abraxis BioScience, a biotech focused on cancer treatments, for $2.9 billion. Abraxis BioScience markets Abraxane, a chemotherapy treatment option for metastatic breast cancer, which netted $314.5 million in 2009, down from $335.6 in 2008, according to an Abraxis annual report.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.